Cost-effectiveness of Empagliflozin in Patients With Heart Failure With Preserved Ejection Fraction
Cost-effectiveness of Empagliflozin in Patients With Heart Failure With Preserved Ejection Fraction is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Cost-effectiveness of Empagliflozin in Patients With Heart Failure With Preserved Ejection Fraction have?
Cost-effectiveness of Empagliflozin in Patients With Heart Failure With Preserved Ejection Fraction has 56 citations in the OpenAlex counts ScholarIQ stores.
When was Cost-effectiveness of Empagliflozin in Patients With Heart Failure With Preserved Ejection Fraction published?
Cost-effectiveness of Empagliflozin in Patients With Heart Failure With Preserved Ejection Fraction has 2022 year in the ScholarIQ index.
What is the open-access status of Cost-effectiveness of Empagliflozin in Patients With Heart Failure With Preserved Ejection Fraction?
Cost-effectiveness of Empagliflozin in Patients With Heart Failure With Preserved Ejection Fraction has green oa status in the ScholarIQ index.
What is the DOI of Cost-effectiveness of Empagliflozin in Patients With Heart Failure With Preserved Ejection Fraction?
The DOI for Cost-effectiveness of Empagliflozin in Patients With Heart Failure With Preserved Ejection Fraction is on the source record.
What is the PMID of Cost-effectiveness of Empagliflozin in Patients With Heart Failure With Preserved Ejection Fraction?
The PMID for Cost-effectiveness of Empagliflozin in Patients With Heart Failure With Preserved Ejection Fraction is on the source record.
What is the OpenAlex record for Cost-effectiveness of Empagliflozin in Patients With Heart Failure With Preserved Ejection Fraction?
The OpenAlex for Cost-effectiveness of Empagliflozin in Patients With Heart Failure With Preserved Ejection Fraction is on the source record.